Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Straus

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Blood Advances|July 30, 2020
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphomaDavid Sermer, Sabela Bobillo, Ahmet Dogan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA MonitoringCaitlin M Stewart, Laure Michaud, Karissa Whiting, et al.
Plos Genetics|January 26, 2013
Susceptibility loci associated with specific and shared subtypes of lymphoid malignanciesJoseph Vijai, Tomas Kirchhoff, Kasmintan A Schrader, et al.
The Lancet. Oncology|February 17, 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyAlison J Moskowitz, Heiko Schöder, Joachim Yahalom, et al.
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Blood|September 7, 2017
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Heiko Schöder, Somali Gavane, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphomaConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood Cancer Journal|July 18, 2020
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood Cancer Journal|February 11, 2022
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphomaFushen Sha, Michelle Okwali, Anna Alperovich, et al.
Blood Advances|October 1, 2020
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapiesDavid Sermer, Connie Batlevi, M Lia Palomba, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Blood Advances|July 30, 2020
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphomaDavid Sermer, Sabela Bobillo, Ahmet Dogan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA MonitoringCaitlin M Stewart, Laure Michaud, Karissa Whiting, et al.
Plos Genetics|January 26, 2013
Susceptibility loci associated with specific and shared subtypes of lymphoid malignanciesJoseph Vijai, Tomas Kirchhoff, Kasmintan A Schrader, et al.
The Lancet. Oncology|February 17, 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyAlison J Moskowitz, Heiko Schöder, Joachim Yahalom, et al.
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Blood|September 7, 2017
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Heiko Schöder, Somali Gavane, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphomaConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood Cancer Journal|July 18, 2020
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood Cancer Journal|February 11, 2022
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphomaFushen Sha, Michelle Okwali, Anna Alperovich, et al.
Blood Advances|October 1, 2020
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapiesDavid Sermer, Connie Batlevi, M Lia Palomba, et al.
Pageof 7